
NASDAQHealthcareMedical - Devices
最新数据
US$0.735
−US$0.0003 · -0.04%
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
前收盘价
US$0.735
−US$0.0003 · -0.04%
盘中时间采用ET。市场数据可能有所延迟。
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
日内区间
当前US$0.735
52周区间
当前US$0.735
盘中时间采用ET。市场数据可能有所延迟。
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
日内区间
当前US$0.735
52周区间
当前US$0.735
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3358.7万 USD | 2805.1万 USD | 2251.9万 USD | 1713.3万 USD | 2323.2万 USD |
| 销货成本 | 2597.9万 USD | 2816万 USD | 2800.4万 USD | 2567.3万 USD | 3097.3万 USD |
| 毛利 | 760.8万 USD | −10.9万 USD | −548.5万 USD | −854万 USD | −774.1万 USD |
| 研究与开发 | 1360.3万 USD | 1459.7万 USD | 1282万 USD | 1286.6万 USD | 978.1万 USD |
| 销售、一般及管理费用 | 3483.6万 USD | 3521.3万 USD | 3825.8万 USD | 4181.3万 USD | 2971万 USD |
| 营业费用 | 5500万 USD | 4981万 USD | 5107.8万 USD | 5467.9万 USD | 3949.1万 USD |
| 利息收入 | 150.9万 USD | 316.4万 USD | 421万 USD | 177.8万 USD | — |
| 利息支出 | 109万 USD | — | — | — | 265万 USD |
| 折旧和摊销 | 325.2万 USD | 336.2万 USD | 310.5万 USD | 283.7万 USD | 152.9万 USD |
| 营业利润 | −4739.2万 USD | −4991.9万 USD | −5656.3万 USD | −6321.9万 USD | −4723.2万 USD |
| 净利润 | −4712.3万 USD | −4688.9万 USD | −5246.7万 USD | −6080.6万 USD | −7352.4万 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$1.88
上涨空间 155.78%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。